Cytek Biosciences (CTKB) Long-Term Deferred Tax (2020 - 2025)

Cytek Biosciences has reported Long-Term Deferred Tax for 6 years, with the latest figure at $38.4 million in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Deferred Tax rose 24.74% year-over-year to $38.4 million; the trailing twelve-month figure through Sep 2025 stood at $38.4 million (up 24.74% YoY), and the FY2024 full-year result was $33.4 million, up 9.47% from the prior year.
• Long-Term Deferred Tax for Q3 2025 stood at $38.4 million, up from $35.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $38.4 million in Q3 2025, with the low at $7.4 million in Q2 2021.
• Historically, Long-Term Deferred Tax has averaged $23.3 million across 5 years, with a median of $25.2 million in 2023.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax surged 125.74% — and 2025, when it increased 3.06%.
• Cytek Biosciences' Long-Term Deferred Tax stood at $9.2 million in 2021, then jumped by 123.03% to $20.5 million in 2022, then soared by 49.02% to $30.5 million in 2023, then rose by 9.47% to $33.4 million in 2024, then increased by 15.04% to $38.4 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $38.4 million (Q3 2025), $35.8 million (Q2 2025), and $33.7 million (Q1 2025), per Business Quant data.